Skip to main content

Table 1 Baseline factors of the total cohort and groups with high and low TMB

From: Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study

  Total
N = 75
Low TMB
(N = 38)
High TMB
(N = 37)
P value
Age (Y)
  < 69 38 (50.7%) 20 (52.6%) 18 (48.6%) 0.730
  ≥ 69 37 (49.3%) 18 (47.4%) 19 (51.4%)  
Gender
Male 57 (76.0%) 28 (73.7%) 29 (78.4%) 0.634
Female 18 (24.0%) 10 (26.3%) 8 (21.6%)  
Race
White 67 (89.3%) 31 (81.6%) 36 (97.3%) 0.015
Black 7 (9.3%) 7 (18.4%) 0 (0.0%)  
Asian 1 (1.3%) 0 (0.0%) 1 (2.7%)  
Diagnosis Year
2005–2010 30 (40.0%) 16 (42.1%) 14 (37.8%) 0.706
2011–2013 45 (60.0%) 22 (57.9%) 23 (62.2%)  
BMI (kg/m2)
  < 26.6 34 (45.3%) 17 (44.7%) 17 (45.9%) 0.906
  ≥ 26.6 35 (46.7%) 18 (47.4%) 17 (45.9%)  
Unknown 6 (8.0%) 3 (7.9%) 3 (8.1%)  
p T stage
pT2 24 (32.0%) 11 (28.9%) 13 (35.1%) 0.676
pT3–4 43 (57.3%) 22 (57.9%) 21 (56.8%)  
Unknown 8 (10.7%) 5 (13.2%) 3 (8.1%)  
p N stage
pN0 42 (56.0%) 19 (50.0%) 23 (62.2%) 0.373
pN1–2 21 (28.0%) 12 (31.6%) 9 (24.3%)  
Unknown 12 (16.0%) 7 (18.4%) 5 (13.5%)  
Stage
Stage II 28 (37.3%) 12 (31.6%) 16 (43.2%) 0.296
Stage III 47 (62.7%) 26 (68.4%) 21 (56.8%)  
Clustering Group
Group A 24 (32.0%) 8 (21.1%) 16 (43.2%) 0.039
Group B 51 (68.0%) 30 (78.9%) 21 (56.8%)  
  1. TMB Tumor mutation burden; BMI Body mass index